

10/762998

=> d his ful

(FILE 'HOME' ENTERED AT 17:26:25 ON 31 JAN 2006)  
SET COST OFF

FILE 'REGISTRY' ENTERED AT 17:26:40 ON 31 JAN 2006

- L1 2 SEA ABB=ON PLU=ON (CALCIUM OR VITAMINS)/CN  
E PHOSPHATE/CN 5
- L2 10 SEA ABB=ON PLU=ON (PHOSPHATE/CN OR "PHOSPHATE (32PO4)"/CN  
OR "PHOSPHATE (H2PO4-)/CN OR "PHOSPHATE (H2PO41-)/CN OR  
"PHOSPHATE (HPO42-)/CN OR "PHOSPHATE (P2O74-)/CN OR  
"PHOSPHATE (P4O123-)/CN) OR ("PHOSPHATE (P5O143-)/CN OR  
"PHOSPHATE (P6O186-)/CN) OR ("PHOSPHATE (PO3-)/CN OR  
"PHOSPHATE (PO31-)/CN OR "PHOSPHATE (PO32-)/CN) OR  
"PHOSPHATE (PO43-)/CN OR "PHOSPHATE (PO4H2-)/CN
- L3 12 SEA ABB=ON PLU=ON L1 OR L2

FILE 'HCAPLUS' ENTERED AT 17:27:13 ON 31 JAN 2006

- L4 50681 SEA ABB=ON PLU=ON (MULTI OR MULTIPLE OR PLURAL?) (S) (SECTI  
ON? OR COMPARTMENT? OR COMPONENT? OR CONTAINER? OR  
SUBCOMPARTMENT? OR SUBCONTAINER?)
- L5 636 SEA ABB=ON PLU=ON L4(S) (PACKAG? OR PACKET OR PACK)
- L6 93 SEA ABB=ON PLU=ON L5 AND (L3 OR FEED? OR FOOD? OR  
SUPPLEMENT? OR NUTRITION? OR NUTRIENT OR VITAMIN OR VIT OR  
MINERAL OR CHEMICAL OR ELECTROLYT? OR PROTEIN OR HERB OR  
HERBAL OR CA OR CALCIUM OR PHOSPHATE OR PO!H#)
- L7 0 SEA ABB=ON PLU=ON L6 AND (CANINE OR DOG OR HORSE OR  
EQUINE OR (CANIS OR C) (W) FAMILIAR? OR (E OR EQUUS) (W) (CABAL  
LUS OR PRZEWA?))

FILE 'REGISTRY' ENTERED AT 17:30:33 ON 31 JAN 2006  
D L3 1-12 IDE

FILE 'HCAPLUS' ENTERED AT 17:30:36 ON 31 JAN 2006  
D QUE L7

FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,  
JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB, FSTA' ENTERED AT  
17:30:36 ON 31 JAN 2006

- L8 15 SEA ABB=ON PLU=ON L7
- L9 13 DUP REM L8 (2 DUPLICATES REMOVED)  
D 1-13 IBIB ABS

FILE 'USPATFULL' ENTERED AT 17:33:31 ON 31 JAN 2006

- L10 851 SEA ABB=ON PLU=ON L5(S) (UNIFIED OR UNIFY? OR UNITAR?)
- L11 453 SEA ABB=ON PLU=ON L10(L) (L3 OR FEED? OR FOOD? OR  
SUPPLEMENT? OR NUTRITION? OR NUTRIENT OR VITAMIN OR VIT OR  
MINERAL OR CHEMICAL OR ELECTROLYT? OR PROTEIN OR HERB OR  
HERBAL OR CA OR CALCIUM OR PHOSPHATE OR PO!H#)
- L12 14 SEA ABB=ON PLU=ON L11(L) (CANINE OR DOG OR HORSE OR  
EQUINE OR (CANIS OR C) (W) FAMILIAR? OR (E OR EQUUS) (W) (CABAL  
LUS OR PRZEWA?))  
D QUE  
D 1-14 IBIB ABS

FILE 'HCAPLUS' ENTERED AT 17:35:00 ON 31 JAN 2006

- L13 2 SEA ABB=ON PLU=ON L5(S) (UNIFIED OR UNIFY? OR UNITAR?)
- L14 1 SEA ABB=ON PLU=ON L13 AND (L3 OR FEED? OR FOOD? OR  
SUPPLEMENT? OR NUTRITION? OR NUTRIENT OR VITAMIN OR VIT OR

Searcher : Shears 571-272-2528

10/762998

MINERAL OR CHEMICAL OR ELECTROLYT? OR PROTEIN OR HERB OR  
HERBAL OR CA OR CALCIUM OR PHOSPHATE OR PO!H#)  
D QUE  
D .BEVSTR

FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,  
JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB, FSTA' ENTERED AT  
17:36:05 ON 31 JAN 2006

L15 7 SEA ABB=ON PLU=ON L14  
L16 6 SEA ABB=ON PLU=ON L15 NOT L8  
L17 6 DUP REM L16 (0 DUPLICATES REMOVED)  
D 1-6 IBIB ABS

FILE 'MEDLINE' ENTERED AT 17:38:52 ON 31 JAN 2006

L18 3365 SEA ABB=ON PLU=ON ((ANIMAL FEED OR DIETARY SUPPLEMENTS  
OR FOOD) AND (MINERALS OR VITAMINS OR PROTEINS OR ELECTROLY  
TES OR CALCIUM OR PHOSPHATES))/CT  
L19 272671 SEA ABB=ON PLU=ON (DOGS OR HORSE)/CT  
L20 147 SEA ABB=ON PLU=ON L18 AND L19  
E FOOD PACKAGING/CT  
L21 911 SEA ABB=ON PLU=ON "FOOD PACKAGING"/CT  
L22 0 SEA ABB=ON PLU=ON L20 AND L21  
L23 0 SEA ABB=ON PLU=ON L21 AND L18  
L24 41 SEA ABB=ON PLU=ON L21 AND (ANIMAL FEED OR DIETARY  
SUPPLEMENTS OR FOOD OR MINERALS OR VITAMINS OR PROTEINS OR  
ELECTROLYTES OR CALCIUM OR PHOSPHATES)/CT  
E ANIMALS/CT 5  
L25 3797871 SEA ABB=ON PLU=ON ANIMALS/CT  
L26 17 SEA ABB=ON PLU=ON L24 AND L25  
D KWIC  
D QUE L22  
D QUE L23  
D QUE L26  
D L26 1-17 .BEVERLYMED

FILE 'HCAPLUS, MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,  
JICST-EPLUS, JAPIO, CABA, AGRICOLA, VETU, VETB, FSTA, USPATFULL'  
ENTERED AT 17:44:59 ON 31 JAN 2006

L27 404 SEA ABB=ON PLU=ON "MINARD R"?/AU  
L28 4 SEA ABB=ON PLU=ON "GISHOLT P"?/AU  
L29 4 SEA ABB=ON PLU=ON L27 AND L28  
L30 404 SEA ABB=ON PLU=ON L27 OR L28  
L31 4 SEA ABB=ON PLU=ON L30 AND L6  
L32 4 SEA ABB=ON PLU=ON L29 OR L31  
L33 3 DUP REM L32 (1 DUPLICATE REMOVED)  
D 1-3 IBIB ABS

FILE 'HOME' ENTERED AT 17:48:34 ON 31 JAN 2006

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2006 HIGHEST RN 873057-98-8  
DICTIONARY FILE UPDATES: 30 JAN 2006 HIGHEST RN 873057-98-8

Searcher : Shears 571-272-2528

10/762998

ACCESSION NUMBER: 2005-141687 [15] WPIDS  
DOC. NO. CPI: C2005-046189  
TITLE: Presenting **food** not intended for human consumption e.g. pizza with pet treats for **dogs**, comprises providing crust, arranging treats on crust to form pizza, wrapping pizza, and packaging wrapped pizza in box.  
DERWENT CLASS: D11  
INVENTOR(S): WEIGERT, R  
PATENT ASSIGNEE(S): (WEIG-I) WEIGERT R  
COUNTRY COUNT: 1  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2005031740	A1	20050210	(200515)*		9

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2005031740	A1 Provisional	US 2003-481193P	20030807
	Provisional	US 2003-515799P	20031030
		US 2004-913113	20040806

PRIORITY APPLN. INFO: US 2004-913113 20040806; US  
2003-481193P 20030807; US  
2003-515799P 20031030

AN 2005-141687 [15] WPIDS

AB US2005031740 A UPAB: 20050303

NOVELTY - Presenting **food** not intended for human consumption, comprises providing a crust; arranging treats on the crust to form a pizza; wrapping the pizza; and packaging the wrapped pizza in a box.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(a) a **food** item not intended for human consumption comprising a crust; treats arranged on the crust; and a box enclosing the crust and treats; and

(b) a method of **packaging** treats not intended for human consumption, comprises providing treats not intended for human consumption; forming the treats into an elongated **food** tube with a cross-section of a desired shape such that the elongated **food** tube comprises **multiple** servings; **packaging** the treats; and providing instructions for preparation of the treats, the instructions including a direction that the treats are not intended for human consumption.

USE - The method is for presenting **food** not intended for human consumption (claimed). It is particularly useful for presenting, serving and packaging a pizza comprising pet treats for **dogs**.

ADVANTAGE - The **food** is presented in a form that requires further preparation prior to serving and providing instructions for the preparation.

DESCRIPTION OF DRAWING(S) - The figure illustrates a method for presentation of **food** or treats for non-human companions.

Dwg.1/7

L9 ANSWER 2 OF 13 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

Searcher : Shears 571-272-2528

10/762998

ACCESSION NUMBER: 2004-419571 [39] WPIDS  
 DOC. NO. NON-CPI: N2004-333037  
 DOC. NO. CPI: C2004-157503  
 TITLE: New chimeric, humanized or CDR grafted antibody or  
 its fragment capable of inhibiting human IL-6, useful  
 for treating immune disorders, e.g. arthritis,  
 inflammations, osteoporosis.  
 DERWENT CLASS: B04 D16 P13 P14  
 INVENTOR(S): GILES-KOMAR, J; KNIGHT, D; PERITT, D; TRIKHA, M;  
 KNIGHT, D M; KOMAR, J G; MOHIT, T  
 PATENT ASSIGNEE(S): (CENZ) CENTOCOR INC  
 COUNTRY COUNT: 102  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2004039826	A1	20040513	(200439)*	EN	117
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW					
BR 2002014168	A	20040914	(200469)		
AU 2002346369	A1	20040525	(200470)		
NO 2004002418	A	20040805	(200515)		
EP 1562968	A1	20050817	(200555)	EN	
R: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR					
TW 2003001134	A	20030701	(200556)	#	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004039826	A1	WO 2002-US36213	20021026
BR 2002014168	A	BR 2002-14168	20021026
		WO 2002-US36213	20021026
AU 2002346369	A1	AU 2002-346369	20021026
NO 2004002418	A	WO 2002-US36213	20021026
		NO 2004-2418	20040610
EP 1562968	A1	EP 2002-784436	20021026
		WO 2002-US36213	20021026
TW 2003001134	A	TW 2002-133208	20021113

FILING DETAILS:

PATENT NO	KIND	PATENT NO
BR 2002014168	A Based on	WO 2004039826
AU 2002346369	A1 Based on	WO 2004039826
EP 1562968	A1 Based on	WO 2004039826

PRIORITY APPLN. INFO: WO 2002-US36213 20021026; US  
 2001-332437P 20011114; US  
 2001-332743P 20011114; TW  
 2002-133208 20021113  
 AN 2004-419571 [39] WPIDS

Searcher : Shears 571-272-2528

AB WO2004039826 A UPAB: 20040621

NOVELTY - A chimeric, humanized or CDR grafted antibody or its fragment capable of inhibiting human IL-6 comprising at least one heavy or light chain complementarity determining region (CDR) derived from the anti-IL-6 murine monoclonal antibody CLB-8 and a constant region derived from one or more human antibodies, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

- (1) an isolated IL-6 antibody encoding nucleic acid;
- (2) an isolated IL-6 antibody or its specified portion or variant comprising the antibody in (1);
- (3) an IL-6 antibody encoding nucleic acid composition comprising the nucleic acid, and a carrier or diluent;
- (4) an antibody vector comprising the nucleic acid;
- (5) a host cell comprising the isolated nucleic acid;
- (6) producing at least one IL-6 antibody or its specified portion or variant;
- (7) an IL-6 antibody composition or specified portion or variant composition comprising the IL-6 antibody or specified portion or variant, and a carrier or diluent;
- (8) treating an immune disorder or disease in a cell, tissue, organ or animal;
- (9) modulating at least cancerous disorder or condition in a cell, tissue, organ or animal;
- (10) a medical device comprising at least one of the antibody cited above;
- (11) a formulation comprising at least one IL-6 antibody or specified portion or variant, and at least one selected from sterile water, sterile buffered water, or at least one preservative;
- (12) treating at least one IL-6 mediated condition by administering the formulation to the patient;
- (13) an article of manufacture for human pharmaceutical use comprising packaging material, and a container comprising a solution or a lyophilized form of at least one IL-6 antibody or its specified portion or variant;
- (14) preparing the formulation; and
- (15) a transgenic animal or plant expressing at least one of the antibody.

ACTIVITY - Immunosuppressive; Antiinflammatory; Antirheumatic; Antiarthritic; Osteopathic.

No biological data given.

MECHANISM OF ACTION - Immunotherapy.

USE - The antibody, its specified portion and variant are useful for treating an immune disease or disorder, e.g. rheumatoid arthritis/seronegative arthropathies, osteoarthritis, or inflammatory bowel disease. (claimed).

Dwg.0/10

L9 ANSWER 3 OF 13 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 2003-362981 [34] WPIDS

DOC. NO. CPI: C2003-095732

TITLE: Sustained release apparatus for controlling of parasitic infection in an animal comprises several sustained release mini-implants or pellets containing sustained release support material and a composition carried in or on support.

DERWENT CLASS: A96 B07 C07 D16 D22

INVENTOR(S): BRANDON, M; MARTINOD, S R

PATENT ASSIGNEE(S): (SMAR-N) SMART DRUG SYSTEMS INC; (BRAN-I) BRANDON M; (MART-I) MARTINOD S R

10/762998

COUNTRY COUNT: 101

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003002102	A1	20030109	(200334)*	EN	22
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW					
EP 1411904	A1	20040428	(200429)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					
AU 2002344685	A1	20030303	(200452)		
BR 2002010631	A	20040727	(200452)		
JP 2004530721	W	20041007	(200466)		75
US 2004241204	A1	20041202	(200481)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003002102	A1	WO 2002-AU865	20020701
EP 1411904	A1	EP 2002-742515	20020701
		WO 2002-AU865	20020701
AU 2002344685	A1	AU 2002-344685	20020701
BR 2002010631	A	BR 2002-10631	20020701
		WO 2002-AU865	20020701
JP 2004530721	W	WO 2002-AU865	20020701
		JP 2003-508341	20020701
US 2004241204	A1	WO 2002-AU865	20020701
		US 2004-482336	20040629

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1411904	A1 Based on	WO 2003002102
AU 2002344685	A1 Based on	WO 2003002102
BR 2002010631	A Based on	WO 2003002102
JP 2004530721	W Based on	WO 2003002102

PRIORITY APPLN. INFO: AU 2001-6025 20010629

AN 2003-362981 [34] WPIDS

AB WO2003002102 A UPAB: 20030529

NOVELTY - Sustained release apparatus comprises several sustained release mini-implants or pellets where the mini-implant (a) comprises sustained release support material (b); and a composition (c) carried in or on (b). (c) comprises at least one pharmaceutically active component (d) and a carrier (e).

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a sustained release kit comprising several sustained release mini implants or pellets packaged for delivery in a single treatment.

ACTIVITY - Anti-parasitic; Virucide.

MECHANISM OF ACTION - None given.

USE - For treating a disease or condition in an animal e.g.

Searcher : Shears 571-272-2528

human, sheep, cattle, goat, **horse**, camel, pig, **dog**, cat, ferret, rabbit, marsupial, buffalo, yack, primate, bird including chicken, geese and turkey, rodent including rat and mice, fish and reptile (claimed); in veterinary applications for control of parasitic infections.

**ADVANTAGE** - The composition provides approximately zero order release of the active agent. (e) permits release of (d) from (c) over an extended period of time. Each miniplant in a first size, provides a blood level of pharmaceutical active of 1.25 - 3 times the desired threshold blood level for a first relatively short time period (preferably 1 - 4 weeks); and in a second size it provides a blood level of pharmaceutical active at or near the desired threshold blood level for a second longer time period (preferably 4 - 52 weeks). Each implant insufficient in size and/or payload individually provides a predetermined desired threshold blood level of pharmaceutical active for treatment of a selected indication. The composition provides increase in rate of release of the pharmaceutical agent. Since the composition comprises a series of mini-implants or pellets; hence it can achieve threshold blood level of a pharmaceutical active required to treat a particular disease. The multi mini-pellet composition permits the treatment of a disease over extended period of time. The composition having double layer structure exhibits unexpected release profile.  
Dwg.0/0

L9 ANSWER 4 OF 13 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN  
 ACCESSION NUMBER: 2004-052145 [05] WPIDS  
 DOC. NO. CPI: C2004-021093  
 TITLE: Modified S immunoglobulin molecule useful for treating immune disorder or diseases especially immune conditions e.g. rheumatoid arthritis, osteoarthritis, inflammatory bowel disease or systematic lupus erythematosus.  
 DERWENT CLASS: B04 C06 D16  
 INVENTOR(S): CAI, A; NASO, M; SCALLON, B J; SCALLON, B  
 PATENT ASSIGNEE(S): (CAIA-I) CAI A; (NASO-I) NASO M; (SCAL-I) SCALLON B J; (CENZ) CENTOCOR INC  
 COUNTRY COUNT: 103  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2003232046	A1	20031218	(200405)*		37
WO 2003105898	A1	20031224	(200406)	EN	
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
AU 2003253621	A1	20031231	(200451)		
EP 1542721	A1	20050622	(200541)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					

## APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
Searcher	:	Shears	571-272-2528

US 2003232046	A1 Provisional	US 2002-388896P	20020614
		US 2003-454948	20030605
WO 2003105898	A1	WO 2003-US17742	20030605
AU 2003253621	A1	AU 2003-253621	20030605
EP 1542721	A1	EP 2003-760235	20030605
		WO 2003-US17742	20030605

## FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003253621	A1 Based on	WO 2003105898
EP 1542721	A1 Based on	WO 2003105898

PRIORITY APPLN. INFO: US 2002-388896P 20020614; US  
2003-454948 20030605

AN 2004-052145 [05] WPIDS

AB US2003232046 A UPAB: 20040120

NOVELTY - Modified S immunoglobulin molecule (I) having an extra constant region immunoglobulin (Ig) domain inserted into the constant region of Ig molecule, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

- (1) a polynucleotide (II) that encodes (I);
- (2) a vector (III) comprising (II);
- (3) a host cell (IV) transfected with (III);
- (4) producing (M1) (I);
- (5) a pharmaceutical composition (V) comprising (I) and a carrier;
- (6) a nucleic acid composition (VI), comprising (II) and a carrier or diluent;
- (7) a medical device comprising (I), where the device is suitable to contacting or administering (I) by at least one mode chosen from intravenous, intraocular, bolus, subcutaneous, respiratory, inhalation, vaginal, rectal, buccal, sublingual, intranasal or transdermal;
- (8) a formulation (VII) comprising (I), or lyophilized form of (I) in a first container and an optical second container, and at least one chosen from the sterile water, sterile buffered water, or at least one preservative chosen from phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride, sodium dehydroacetate and thimerosal, or its mixtures, in an aqueous diluent;
- (9) an article (VIII) of manufacture for human pharmaceutical use, comprising packaging material and a container having a solution or a lyophilized form of (I);
- (10) preparing a formulation of (I), involves admixing (I) in at least one buffer containing saline or a salt;
- (11) a transgenic animal or plant (IX) expression of (I);
- (12) (I) produced by (M1); and
- (13) providing added flexibility to, and spatial distance between Fab domains of an antibody by incorporating an extra constant region Ig domain into the constant region of an antibody.

ACTIVITY - Antirheumatic; Antiarthritic; Osteopathic; Antiinflammatory; Dermatological; Immunosuppressive; Ophthalmological; Antibacterial; Virucide; Anti-HIV; Vasotropic; Antiallergic; Hepatotropic.

No biological data given.

MECHANISM OF ACTION - None given.



USE - (I) is useful for treating an immune disorder or disease in a cell, tissue, organ or animal (primate e.g., monkey or human) which involves administering at least one selected immune modulating effective amount of (I). The immune condition is chosen from rheumatoid arthritis/seronegative arthropathies, osteoarthritis, inflammatory bowel disease, systematic lupus erythematosus, iridocyclitis/uvetis/optic neuritis, idiopathic pulmonary fibrosis, systemic vasculitis/wegener's granulomatosis, etc. (I) is useful for modulating at least one infectious or cancerous disorder or condition in a cell, tissue, organ or animal. The infection or cancerous disorder or condition is chosen from acute or chronic bacterial infection, acute and chronic parasitic or infectious processes, including bacterial, viral and fungal infections, HIV infection/HIV neuropathy, meningitis, hepatitis, septic arthritis, peritonitis, pneumonia, epiglottitis, etc. (V) is useful for treating or protecting against an infection in a subject (all claimed).

ADVANTAGE - (I) exhibits added flexibility and spatial distance between two Fab domains, increase in neutralization potency or higher affinity for target parent molecule. (I) serves as better surrogate antibodies, enables to form higher-order immune complexes or enhances interaction between a receptor and its ligand.

DESCRIPTION OF DRAWING(S) - The figure shows schematic comparison of normal antibody structure with S-antibody structure.  
Dwg.1/6

L9 ANSWER 5 OF 13 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN  
 ACCESSION NUMBER: 2003-103204 [09] WPIDS  
 DOC. NO. CPI: C2003-025934  
 TITLE: New isolated REG-like **protein** (RELP) human immunoglobulin derived **protein** or specified portion or variant, useful for preventing or treating a RELP **protein** mediated condition or malignant condition, e.g. cancer.  
 DERWENT CLASS: B04 D16  
 INVENTOR(S): HEISKALA, M  
 PATENT ASSIGNEE(S): (CENZ) CENTOCOR INC; (HEIS-I) HEISKALA M  
 COUNTRY COUNT: 100  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002074916	A2	20020926	(200309)*	EN	101
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW					
AU 2002257052	A1	20021003	(200432)		
US 2004167086	A1	20040826	(200457)		

## APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002074916	A2	WO 2002-US7945	20020314
AU 2002257052	A1	AU 2002-257052	20020314
US 2004167086	A1 Provisional	US 2001-276305P	20010316

## FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002257052	A1 Based on	WO 2002074916

PRIORITY APPLN. INFO: US 2001-276305P 20010316; US  
2002-99791 20020314

AN 2003-103204 [09] WPIDS

AB WO 200274916 A UPAB: 20030206

NOVELTY - A new isolated REG-like **protein** (RELP) human immunoglobulin (Ig) derived **protein** or specified portion or variant (I), comprises:

- (a) a human variable and constant region; or
- (b) an isolated human Ig derived **protein** or specified portion or variant encoded by a nucleic acid.

DETAILED DESCRIPTION - A new isolated REG-like **protein** (RELP) human immunoglobulin (Ig) derived **protein** or specified portion or variant (I), comprises:

- (a) a human variable and constant region, where (I) specifically binds at least one epitope comprising at least 1-3, to the entire amino acid sequence selected from 9 sequences of 17-158 amino acids fully defined in the specification; or

- (b) an isolated human Ig derived **protein** or specified portion or variant encoded by a nucleic acid.

INDEPENDENT CLAIMS are also included for the following:

- (1) an isolated RELP **protein** human Ig derived **protein** encoding nucleic acid (II) comprises a nucleic acid that encodes (I);
- (2) a RELP **protein** human Ig derived **protein** encoding nucleic acid composition (III), comprising (II) and a carrier or diluent;

- (3) a human Ig derived **protein** vector (IV) comprising (II);

- (4) a mammalian host cell (V) comprising (II);

- (5) a RELP **protein** human Ig derived **protein** (VI) or specified portion or variant composition, comprising (I) and a carrier or diluent;

- (6) a medical device comprising (I), where the device is suitable for contacting or administering (I);

- (7) a human Ig light chain RELP **protein** (VII) or its portion comprising at least one portion of a variable region of at least one human Ig derived **protein** fragment cited above;

- (8) a human Ig heavy chain (VIII) or its portion comprising at least one portion of a variable region of at least one RELP **protein** human Ig derived **protein** fragment cited above;

- (9) a human Ig derived **protein** (IX) or specified portion or variant that binds the same epitope or antigenic region as (I);

- (10) formulations (X) comprising (I) in a lyophilized form in a first container, and an optional second container comprising at least one of sterile water, sterile buffered water, or at least one preservative selected from the group of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkylparaben, benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal, or their mixtures in an aqueous diluent;

- (11) treating (M1) a RELP **protein** mediated condition, a malignant condition or disease condition in a cell, tissue, organ or animal;
- (12) producing (M2) (I);
- (13) preparing (M3) a formulation of (I);
- (14) an article (XI) of manufacture for human pharmaceutical use, comprising packaging material and a container consisting of a solution or a lyophilized form of (I); and
- (15) a transgenic animal (XII) or plant (XIII) expressing at least one (I), (VI) or (IX).

ACTIVITY - Cytostatic.

No biological data given.

MECHANISM OF ACTION - Ig Agonist; **Protein** Therapy.

USE - The RELP human Ig derived **protein** or specified portion or variant is useful for preventing or treating a RELP **protein** mediated condition, malignant condition or disease condition, e.g. cancer. The nucleic acids can be used in producing RELP Ig derived **protein**.

Dwg.0/4

L9 ANSWER 6 OF 13 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN  
 ACCESSION NUMBER: 2002-740810 [80] WPIDS  
 DOC. NO. CPI: C2002-209786  
 TITLE: New isolated chronic obstructive pulmonary disease (COPD) related immunoglobulin derived **protein** or variant, useful for treating COPD-related conditions such as emphysema, asthma, chronic bronchitis or airflow obstruction.  
 DERWENT CLASS: B04 C06 D16  
 INVENTOR(S): TORPHY, T J; TORPHY, T  
 PATENT ASSIGNEE(S): (TORP-I) TORPHY T J; (CENZ) CENTOCOR INC  
 COUNTRY COUNT: 97  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002072788	A2	20020919	(200280)*	EN	130
RW:	AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW				
	MZ NL OA PT SD SE SL SZ TR TZ UG ZW				
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE				
	DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG				
	KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL				
	PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW				
US 2003017150	A1	20030123	(200310)		
EP 1379275	A2	20040114	(200410)	EN	
R:	AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL				
	PT RO SE SI TR				
AU 2002254234	A1	20020924	(200433)		
JP 2004528031	W	20040916	(200461)		216

# APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002072788	A2	WO 2002-US7946	20020314
US 2003017150	A1 Provisional	US 2001-275652P	20010314
		US 2002-99007	20020314
EP 1379275	A2	EP 2002-723456	20020314
		WO 2002-US7946	20020314

Searcher : Shears 571-272-2528

10/762998

AU 2002254234 A1  
JP 2004528031 W

AU 2002-254234 20020314  
JP 2002-571844 20020314  
WO 2002-US7946 20020314

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1379275	A2 Based on	WO 2002072788
AU 2002254234	A1 Based on	WO 2002072788
JP 2004528031	W Based on	WO 2002072788

PRIORITY APPLN. INFO: US 2001-275652P 20010314; US  
2002-99007 20020314

AN 2002-740810 [80] WPIDS

AB WO 200272788 A UPAB: 20021212

NOVELTY - An isolated chronic obstructive pulmonary disease (COPD) related immunoglobulin (Ig) derived **protein** or variant (I), comprising at least one immunoglobulin complementarity determining region (CDR), or at least a ligand binding region (LBR) that specifically binds at least one COPD related **protein**, is new.

DETAILED DESCRIPTION - An isolated chronic obstructive pulmonary disease (COPD) related immunoglobulin (Ig) derived **protein** or variant (I), comprising at least one immunoglobulin complementarity determining region (CDR), or at least a ligand binding region (LBR) that specifically binds at least one COPD related **protein**, is new.

(I) specifically binds to at least one epitope comprising at least 1-3, to the entire amino acid sequence, selected from a human tissue necrosis factor alpha (TNF), an interleukin-6 (IL-6), an interleukin-8 (IL-8), an epidermal growth factor (EGF), a CD-8 or a CD018. This COPD-related Ig derived **protein** or specified portion or variant can also comprise at least COPD-related **protein** binding region selected from at least 1-3 amino acids selected from TNF, IL-6, IL-8, EGF, CD-8, or CD-18 receptor or ligand.

INDEPENDENT CLAIMS are also included for the following:

(1) an isolated COPD-related human Ig derived **protein** encoding nucleic acid that hybridizes under stringent conditions, or has at least 95% identity to a nucleic acid encoding (I);

(2) an COPD-related human Ig derived **protein** encoding nucleic acid composition, comprising the nucleic acid and a carrier;

(3) a human Ig derived **protein** vector comprising the nucleic acid of (1);

(4) a mammalian host cell comprising the nucleic acid;

(5) methods for producing at least one (I);

(6) a COPD-related human Ig derived **protein** or specified portion or variant composition comprising at least one (I), and a carrier or diluent;

(7) a method for treating a COPD-related condition in a cell, tissue, organ or animal;

(8) a medical device comprising (I), suitable for contacting or administering (I) by at least one mode selected from intravenous, intramuscular, bolus, intraperitoneal, subcutaneous, respiratory, inhalation, nasal, vaginal, rectal, buccal, sublingual, intranasal, intradermal, subdermal or transdermal;

(9) a human Ig light or heavy chain COPD-related, or its portion, comprising at least a portion of a variable region comprising the at least one human Ig derived **protein** fragment;

Searcher : Shears 571-272-2528

(10) a human Ig derived **protein** or specified portion, or its variant, which binds to the same epitope or antigenic region of (I);

(11) a formulation comprising at least one (I), and sterile water or sterile buffered water, or at least one preservative such as phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkyl paraben, benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal, or their mixtures in an aqueous diluent;

(12) an article of manufacture for human pharmaceutical use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one (I);

(13) a method for preparing the formulation by admixing at least one (I) in at least one buffer containing saline or salt; and

(14) a transgenic animal or plant expressing at least one human Ig derived **protein**.

ACTIVITY - Antiinflammatory; Antiasthmatic; Antiarthritic; Osteopathic; Antiinflammatory; Dermatological; Immunosuppressive; Cardiant; Antiarteriosclerotic; Hypotensive; Antianginal; Antibacterial; Virucide; Fungicide; Parasiticide; Cytostatic; Nootropic; Neuroprotective; Antiparkinsonian.

Test details are described but no results are given.

MECHANISM OF ACTION - Gene therapy.

USE - The **proteins**, nucleic acids, formulations and compositions are useful for treating COPD-related conditions such as emphysema, asthma, chronic bronchitis or airflow obstruction (claimed). They are also useful for treating or modulating COPD associated immune related diseases (arthritis, osteoarthritis, allergic rhinitis, lupus), cardiovascular diseases (congestive heart failure, arteriosclerosis, hypertension, angina pectoris), infections (bacterial, viral, fungal, parasitic), malignant diseases (cancer, leukemia, Hodgkin's disease) and/or neurologic diseases Huntington's chorea, Parkinson's disease, multiple sclerosis).

Dwg.0/1

L9 ANSWER 7 OF 13 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN  
 ACCESSION NUMBER: 2001-283861 [30] WPIDS  
 DOC. NO. NON-CPI: N2001-202431  
 DOC. NO. CPI: C2001-086673  
 TITLE: **Package system for administering feed materials to a horse, comprises multiple-sectioned unitary package with sections containing equine supplement feed materials.**  
 DERWENT CLASS: D13 P14  
 INVENTOR(S): GISHOLT, P C; MINARD, R M  
 PATENT ASSIGNEE(S): (PREC-N) PRECISION EQUINE SUPPLEMENT SERVICES LLC;  
 (PREC-N) PRECISION EQUINE SUPPLEMENT; (SMAR-N) SMARTPAK EQUINE LLC  
 COUNTRY COUNT: 26  
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 1093719	A2	20010425	(200130)*	EN	20
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL					
PT RO SE SI					
US 6733771	B1	20040511	(200431)		

10/762998

US 2004151760 A1 20040805 (200452)#

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 1093719	A2	EP 2000-610105	20001006
US 6733771	B1 Provisional	US 1999-158207P	19991007
		US 2000-679752	20001005
US 2004151760	A1 Cont of	US 2000-679752	20001005
		US 2004-762998	20040122

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 2004151760	A1 Cont of	US 6733771

PRIORITY APPLN. INFO: US 1999-158207P 19991007; US  
2000-679752 20001005; US  
2004-762998 20040122

AN 2001-283861 [30] WPIDS  
AB EP 1093719 A UPAB: 20010603  
NOVELTY - **Package** system for administering **feed** materials to a **horse** comprises **multiple-sectioned** unitary **package** positioned at a **horse** table. Each of the **package sections** (2) contains **equine supplement feed** materials.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method for filling an animal **feed** material **package**, which includes providing a dispensing apparatus that can dispense solid materials, and dispensing animal **feed** material from the apparatus into a **multi-sectioned** unitary **package**; and

(2) a method for processing orders for packaged animal **feed** material through at least one communications network, which comprises placing an order for packaged animal **feed** material, and receiving data and any parameters of ordered **feed** materials over the communications network. The customer is capable of providing automated input of parameters of the packaged material.

USE - For administering **feed** materials to an animal including livestock or a domestic animal, particularly a **horse** (claimed). The package is especially useful in **horse** stables, i.e. buildings that house one or more **horses**. It is also useful for administration to a variety of other animals including **dogs** and camels.

ADVANTAGE - The **package** is easy to handle as a single unified whole and comprises **multiple** sub-containers or sub-compartments capable of maintaining separation between several solid and/or liquid animal **supplements** or **feed** materials. Specified amount of the **feed** materials can also be placed in each **compartment** to provide a customized **feed** or dosage amount for a given animal.

DESCRIPTION OF DRAWING(S) - The figure shows the inventive package system.

Package sections or compartments 2

Searcher : Shears 571-272-2528

Dwg.1/23

L9 ANSWER 8 OF 13 JICST-EPlus COPYRIGHT 2006 JST on STN DUPLICATE 1  
 ACCESSION NUMBER: 1010633906 JICST-EPlus  
 TITLE: Immunohistochemical demonstration of chromogranin A in  
 endocrine organs of the rat and **horse** by use  
 of region-specific antibodies.  
 AUTHOR: HASHIMOTO Y; OHKI H; IWANAGA T  
 SATO F  
 YANAIHARA N  
 CORPORATE SOURCE: Hokkaido Univ., Sapporo  
 Japan Racing Assoc., Utsunomia  
 Yanaihara Inst.fujinomiya, Jpn  
 SOURCE: Jpn J Vet Res, (2001) vol. 49, no. 1, pp. 3-17. Journal  
 Code: F0717A (Fig. 5, Tbl. 2, Ref. 60)  
 CODEN: JJVRAE; ISSN: 0047-1917  
 PUB. COUNTRY: Japan  
 DOCUMENT TYPE: Journal; Article  
 LANGUAGE: English  
 STATUS: New

AB Chromogranin A (CgA) is an acidic glycoprotein that is co-stored with  
 hormones or neurotransmitters in granular **components** of  
 endocrine cells and neurons, and released together with them in  
 response to adequate stimulation. In addition to acting as a  
**packaging protein**, CgA functions as a precursor  
 molecule that yields several bioactive peptides by proteolytic  
 cleavage. The purpose of this study is to elucidate how different the  
 processing of CgA is among endocrine tissues by immunostaining using  
**multiple** region-specific antisera, and to evaluate the  
 availability of region-specific antisera. When various endocrine  
 organs of rats were immunostained with four region-specific antisera  
 against rat CgA (CgA 1-28, 94-130, 296-314, and 359-389), all  
 amine/peptide-secreting endocrine tissues except the pineal body were  
 stained positively. The adrenal medulla and gastric endocrine cells  
 were equally intensely immunoreactive to all four antisera, while the  
 other endocrine tissues, represented by pancreatic islets, showed  
 different staining patterns depending on the antiserum. These results  
 suggest that the processing of CgA differs from tissue to tissue. An  
 antiserum against **horse** CgA 335-365, corresponding to rat  
 CgA 359-389 which shows the highest concentration in the plasma and  
 urine of the rat, again stained all endocrine tissues of the  
**horse** except the pineal body. Therefore, the anti-  
**horse** CgA 335-365 serum is useful for immuno-histochemical  
 survey of **horse** CgA, and may make possible the establishment  
 of a CgA assay system for the measurement of CgA in the plasma, urine  
 and saliva. (author abst.)

L9 ANSWER 9 OF 13 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN  
 ACCESSION NUMBER: 2000-421588 [36] WPIDS  
 CROSS REFERENCE: 2000-398802 [23]  
 DOC. NO. NON-CPI: N2000-314471  
 DOC. NO. CPI: C2000-127452  
 TITLE: Gas impermeable container for dry pet **food**,  
 comprises walls having airtight seal and space devoid  
 of oxygen scavengers, nitrogen fill or vacuum  
 conditions.  
 DERWENT CLASS: A92 D13 Q34  
 INVENTOR(S): JONES, D R; LEWIS, L D  
 PATENT ASSIGNEE(S): (SEAL-N) SEAL ROCK TECHNOLOGIES INC

10/762998

COUNTRY COUNT: 1  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 6063414	A	20000516	(200036)*		7

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 6063414	A	US 1997-912410	19970818

PRIORITY APPLN. INFO: US 1997-912410 19970818

AN 2000-421588 [36] WPIDS

CR 2000-398802 [23]

AB US 6063414 A UPAB: 20000801

NOVELTY - A gas impermeable container comprises at least two walls forming an airtight seal and an airtight space devoid of oxygen scavengers, nitrogen fill or vacuum conditions. It contains a dry pet **food** having moisture level of 5-15 weight%, a soluble fiber content of greater than 3 weight%, a water activity of 0.5-0.8 and no preservatives.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(a) a dry pet **food** of moisture level 5-15 weight% free of added **chemical** preservatives, anti-oxidants, sugars, and anti-mycotics but including a nature edible fiber containing a soluble fiber (3-15 weight%) which causes water activity of at most 0.7; and

(b) decreasing deterioration of dry **dog food** by decreasing water activity to at most 0.7 by including natural edible soluble fiber (greater than 3 weight%).

The **food** is packaged in a gas impermeable package devoid of oxygen scavengers, nitrogen fill or vacuum conditions.

USE - For companion pets e.g. **dogs** and cats.

ADVANTAGE - The invention inhibits the microbial growth and oxidation without using vacuum packaging or addition of **chemical** preservatives. It provides improved palatability and maintained freshness and **nutritional** value of the dry pet **food**. It also permits prolonged shelf life and reduced production, storage, and transportation costs.  
Dwg.0/0

L9 ANSWER 10 OF 13 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 2000-398802 [34] WPIDS

CROSS REFERENCE: 2000-421588 [32]

DOC. NO. NON-CPI: N2000-298688

DOC. NO. CPI: C2000-120347

TITLE: Gas impermeable container and dry pet **food** for preserving pet **food** for **dog**, which does not contain any preservative or require removal of oxygen from package.

DERWENT CLASS: A92 D13 Q34

INVENTOR(S): JONES, D R; LEWIS, L D

PATENT ASSIGNEE(S): (SEAL-N) SEAL ROCK TECHNOLOGIES INC

COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
-----------	------	------	------	----	----

Searcher : Shears 571-272-2528



PATENT NO	KIND	APPLICATION	DATE
US 6042857	A Cont of	US 1997-912410	19970818
		US 1999-318179	19990525

L9 ANSWER 11 OF 13 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN  
ACCESSION NUMBER: 2000-118301 [11] WPIDS  
CROSS REFERENCE: 2002-354019 [39]  
DOC. NO. CPI: C2000-036455  
TITLE: New FSH (follicle stimulating hormone) formulations,  
useful for treating infertility.  
DERWENT CLASS: B04 B05 C03  
INVENTOR(S): HOFFMANN, J A; LU, J; HOFFMAN, J A  
PATENT ASSIGNEE(S): (ELIL) LILLY & CO ELI; (HOFF-I) HOFFMAN J A; (LUJJ-I)  
LU J; (HOFF-I) HOFFMANN J A  
COUNTRY COUNT: 87  
PATENT INFORMATION:

Searcher : Shears 571-272-2528

10/762998

WO 2000004913 A1 20000203 (200014) EN  
RW: EA GH GM KE LS MW OA SD SL SZ UG ZW  
W: AE AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GD GE GH GM HR HU  
ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW  
MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN YU  
ZA ZW  
AU 9949980 A 20000214 (200029)  
NO 2001000326 A 20010320 (200130)  
BR 9912243 A 20011016 (200170)  
CN 1309567 A 20010822 (200175)  
KR 2001083126 A 20010831 (200215)  
ZA 2001000190 A 20020327 (200230) 138  
MX 2001000621 A1 20010601 (200235)  
JP 2002521342 W 20020716 (200261) 90  
US 2002165146 A1 20021107 (200275)  
EP 974359 B1 20021204 (200303) EN  
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC NL PT  
RO SE SI  
DE 69904262 E 20030116 (200313)  
ES 2183486 T3 20030316 (200325)  
US 2003166525 A1 20030904 (200359)  
NZ 508874 A 20040326 (200425)  
AU 776823 B2 20040923 (200480)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 974359	A2	EP 1999-305664	19990716
WO 2000004913	A1	WO 1999-US16031	19990715
AU 9949980	A	AU 1999-49980	19990715
NO 2001000326	A	WO 1999-US16031	19990715
		NO 2001-326	20010119
BR 9912243	A	BR 1999-12243	19990715
		WO 1999-US16031	19990715
CN 1309567	A	CN 1999-808813	19990715
KR 2001083126	A	KR 2001-700781	20010118
ZA 2001000190	A	ZA 2001-190	20010108
MX 2001000621	A1	MX 2001-621	20010117
JP 2002521342	W	WO 1999-US16031	19990715
		JP 2000-560906	19990715
US 2002165146	A1	US 1998-93906P	19980723
	Provisional	US 1998-94611P	19980730
	Provisional	US 1998-94767P	19980731
	Provisional	US 1998-98711P	19980901
	Provisional	US 1998-100696P	19980917
	Div ex	WO 1999-US16031	19990715
	Div ex	US 2001-744431	20010122
		US 2001-973918	20011010
EP 974359	B1	EP 1999-305664	19990716
	Related to	EP 2001-130213	19990716
DE 69904262	E	DE 1999-604262	19990716
		EP 1999-305664	19990716
ES 2183486	T3	EP 1999-305664	19990716
US 2003166525	A1	US 1998-93906P	19980723
	Provisional	US 1998-94611P	19980730
	Provisional	US 1998-94767P	19980731
	Provisional	US 1998-98711P	19980901
	Provisional	US 1998-100696P	19980917

Searcher : Shears 571-272-2528

10/762998

		Div ex	WO 1999-US16031	19990715
		Div ex	US 2001-744431	20010122
			US 2001-928198	20010810
NZ 508874	A		NZ 1999-508874	19990715
			WO 1999-US16031	19990715
AU 776823	B2		AU 1999-49980	19990715

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9949980	A Based on	WO 2000004913
BR 9912243	A Based on	WO 2000004913
JP 2002521342	W Based on	WO 2000004913
EP 974359	B1 Related to	EP 1188444
DE 69904262	E Based on	EP 974359
ES 2183486	T3 Based on	EP 974359
NZ 508874	A Based on	WO 2000004913
AU 776823	B2 Previous Publ. Based on	AU 9949980 WO 2000004913

PRIORITY APPLN. INFO: US 1998-100696P 19980917; US  
 1998-93906P 19980723; US  
 1998-94611P 19980730; US  
 1998-94767P 19980731; US  
 1998-98711P 19980901; US  
 2001-744431 20010122; US  
 2001-973918 20011010; US  
 2001-928198 20010810

AN 2000-118301 [11] WPIDS

CR 2002-354019 [39]

AB EP 974359 A UPAB: 20041213

NOVELTY - A formulation (I) comprising FSH (II) (follicle stimulating hormone) or an FSH variant containing an alpha and beta subunit and a preservative (III) in an aqueous diluent, is new.

DETAILED DESCRIPTION - A formulation (I) comprising FSH (II) (follicle stimulating hormone) or an FSH variant containing an alpha and beta subunit and a preservative (III) selected from phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkylparaben (methyl, ethyl, propyl, butyl), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal, or mixtures of these together in an aqueous diluent, is new.

INDEPENDENT CLAIMS are also included for the following:

(1) a process (IV) for preparing (I), comprising mixing (II) or a variant of (II) with (III) in an aqueous diluent;

(2) an article of manufacture (V) comprising a vial containing a solution of (II) or a variant of (II) and (III), and packaging material which comprises a label which indicates that the solution may be held over a period of 24 hours or greater;

(3) an article of manufacture (VI), comprising a first vial containing lyophilized (II) or a variant of (II), a second vial comprising (III), and packaging material comprising a label which instructs a patient to reconstitute (II) in (III) for use over a period of 24 hours or greater;

(4) a stable formulation (VII), comprising at least 1 (II) or a variant of (II) and a **phosphate** buffer containing saline or salt, where (II) or a variant of (II) comprises at least 90% (II) or variant dimers after 60 days at 23 deg. C;

(5) a process (VIII) for preparing (VII); and

Searcher : Shears 571-272-2528

10/762998

(6) a formulation (IX) comprising a first vial containing a lyophilized (II) or variant of (II) and a second vial containing **phosphate** buffer containing saline or salt.

ACTIVITY - Antiinfertility.

MECHANISM OF ACTION - Stimulates ovulation.

USE - At least one alpha or beta polypeptide of (II) or a variant of (II) is used to prepare a preserved formulation adapted for administration over a period of 24 hours or greater (claimed). At least one (II) or a variant of (II) is used in the preparation of a non preserved formulation, adapted in the same way as above (claimed). (I) and (VII) may be used to treat infertility in a human, sheep, cow, pig, **horse** or rabbit (claimed).

ADVANTAGE - The new formulations are more stable for use in therapy than prior art which allows the extension of treatment regimes. They can also be safely stored at temperatures from 2 to 40 deg. C whilst retaining the biological activity for extended periods of time. The single solution or dual vial can be reused multiple times and are suitable for single or multiple cycles of treatment, providing a more convenient regime, compared to prior art formulations that are only useful for immediate use.

Dwg.0/0

L9 ANSWER 12 OF 13 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN  
ACCESSION NUMBER: 1990-200919 [26] WPIDS  
DOC. NO. NON-CPI: N1990-156369  
DOC. NO. CPI: C1990-086968  
TITLE: Package collator forming serial packages into pairs -  
by **feeding** alternate packages to conveyors  
of different lengths of travel to a common point.  
DERWENT CLASS: A92 D12 Q31  
INVENTOR(S): THOMPSON, R F  
PATENT ASSIGNEE(S): (THOM-I) THOMPSON R F  
COUNTRY COUNT: 1  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 4931131	A	19900605	(199026)*		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 4931131	A	US 1989-360993	19890602

PRIORITY APPLN. INFO: US 1989-360993 19890602

AN 1990-200919 [26] WPIDS

AB US 4931131 A UPAB: 19930928

**Multiple packages** oriented in line one after another are transferred along a **feed** conveyor to the entry of a first and a second conveyor having different length transfer **sections** to a common exit point. The leading **package** of each successive in line **package** pair is fed to a **package** seat on one conveyor whilst the trailing **package** of the same **package** pair is fed to a **package** seat on the other conveyor, **package** seats on one conveyor are provided with vacuum holding systems to hold the **packages** in the seats on that conveyor, and the differences

Searcher : Shears 571-272-2528

10/762998

in the conveyor lengths are such that the **packages** of each pair are translated from in-line orientation into face to face paired orientation at the exit points of the conveyors.

USE/ADVANTAGE - Particularly in the packaging of sausages, e.g. hot **dogs** where two flat packs of 4 or 6 hot **dogs** are assembled in face to face relation and banded together. Allows shrink wrapped packages with curved or wavy facing surfaces to be accurately located face to face and banded to form a neat rectangular package. @  
1/7@

L9 ANSWER 13 OF 13 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN  
DUPLICATE 2

ACCESSION NUMBER: 1980-86094C [48] WPIDS  
TITLE: Sealed **multi-compartment food package** - of plastics with beaded strips in lid for opening **compartments** individually.  
DERWENT CLASS: A92 Q34  
PATENT ASSIGNEE(S): (HOLI-I) HOLIDAY A; (MANN-I) MANN A V  
COUNTRY COUNT: 1  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 4232787	A	19801111	(198048)*		
US 31571	E	19840501	(198420)		

PRIORITY APPLN. INFO: US 1979-26136 19790402; US  
1982-439929 19821108

AN 1980-86094C [48] WPIDS  
AB US 4232787 A UPAB: 19930902

A package includes a base with compartments and covered air-tightly by a lid with a beaded strip formed in it and extending along each compartment so that each can be opened without disturbing the integrity of the other.  
The base and lid are pref. of heat-sealable plastics and the lid can be removed to allow access to all compartments. The package is e.g. for hot **dogs** and the plastics e.g. low-density polyethylene or heavy plasticised PVC.

FILE 'USPATFULL' ENTERED AT 17:33:31 ON 31 JAN 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 31 Jan 2006. (20060131/PD)  
FILE LAST UPDATED: 31 Jan 2006 (20060131/ED)  
HIGHEST GRANTED PATENT NUMBER: US6993790  
HIGHEST APPLICATION PUBLICATION NUMBER: US2006021102  
CA INDEXING IS CURRENT THROUGH 31 Jan 2006 (20060131/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 31 Jan 2006 (20060131/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

L1 2 SEA FILE=REGISTRY ABB=ON PLU=ON (CALCIUM OR VITAMINS)/CN

L2 10 SEA FILE=REGISTRY ABB=ON PLU=ON (PHOSPHATE/CN OR  
"PHOSPHATE (32PO4)"/CN OR "PHOSPHATE (H2PO4-)"/CN OR

Searcher : Shears 571-272-2528

10/762998

"PHOSPHATE (H2PO41-)/CN OR "PHOSPHATE (HPO42-)/CN OR  
"PHOSPHATE (P2O74-)/CN OR "PHOSPHATE (P4O123-)/CN) OR  
("PHOSPHATE (P5O143-)/CN OR "PHOSPHATE (P6O186-)/CN) OR  
("PHOSPHATE (PO3-)/CN OR "PHOSPHATE (PO31-)/CN OR  
"PHOSPHATE (PO32-)/CN) OR "PHOSPHATE (PO43-)/CN OR  
"PHOSPHATE (PO4H2-)/CN

L3 12 SEA FILE=REGISTRY ABB=ON PLU=ON L1 OR L2  
L4 50681 SEA FILE=HCAPLUS ABB=ON PLU=ON (MULTI OR MULTIPLE OR  
PLURAL?) (S) (SECTION? OR COMPARTMENT? OR COMPONENT? OR  
CONTAINER? OR SUBCOMPARTMENT? OR SUBCONTAINER?)  
L5 636 SEA FILE=HCAPLUS ABB=ON PLU=ON L4(S) (PACKAG? OR PACKET  
OR PACK)  
L10 851 SEA FILE=USPATFULL ABB=ON PLU=ON L5(S) (UNIFIED OR UNIFY?  
OR UNITAR?)  
L11 453 SEA FILE=USPATFULL ABB=ON PLU=ON L10(L) (L3 OR FEED? OR  
FOOD? OR SUPPLEMENT? OR NUTRITION? OR NUTRIENT OR VITAMIN  
OR VIT OR MINERAL OR CHEMICAL OR ELECTROLYT? OR PROTEIN OR  
HERB OR HERBAL OR CA OR CALCIUM OR PHOSPHATE OR PO!H#)  
L12 14 SEA FILE=USPATFULL ABB=ON PLU=ON L11(L) (CANINE OR DOG OR  
HORSE OR EQUINE OR (CANIS OR C) (W) FAMILIAR? OR (E OR  
EQUUS) (W) (CABALLUS OR PRZEWAŁ?))

L12 ANSWER 1 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2005:150901 USPATFULL

TITLE: Packaging for eliminating off-odors

INVENTOR(S): Brown, Martha Jo Meadows, Grapevine, TX, UNITED  
STATES

Licker, Jonathan Louis, McKinney, TX, UNITED STATES  
Zbuchalski, Michael R., Plano, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005129812	A1	20050616
APPLICATION INFO.:	US 2003-734426	A1	20031212 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK, NY, 10019, US		
NUMBER OF CLAIMS:	43		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	876		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Packaging materials and packages that transfer off-odor eliminating compounds to foods and other products via the vapor phase are disclosed. The present invention provides a source of desired off-odor eliminating compound, a suitable environment for vapor transfer, and an appropriate product substrate to which an off-odor eliminating compound is added. Examples of the source of off-odor eliminating compound can be a packaging film containing off-odor eliminating compound, a sachet of absorbed flavor material, a tape or label applied to the inside of a package, and a flavor diffusing granule, or alternatively an active system for delivering a vapor to the environment. Alternatively, the off-odor eliminating compounds can be applied topically, directly to the food or other product. In one preferred embodiment, a sulphur scavenging material is used as the off-odor eliminating compound. Materials that are preferably treated using the present invention include snacks, confections, baked goods, fresh plant materials, cereals and beverages, as well

Searcher : Shears 571-272-2528

as non-food products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2005:136890 USPATFULL

TITLE: Use of a closed communication service for social support networks to diagnose and treat conditions in subjects

INVENTOR(S): Williams, Michael David, Boulder, CO, UNITED STATES  
Hudnut, Paul S., Fort Collins, CO, UNITED STATES  
Davoust, Paul, Louisville, CO, UNITED STATES

PATENT ASSIGNEE(S): CARINGFAMILY, LLC, Louisville, CO, UNITED STATES  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005117527	A1	20050602
APPLICATION INFO.:	US 2004-971916	A1	20041023 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-514172P	20031024 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FAEGRE & BENSON LLP, PATENT DOCKETING, 2200 WELLS FARGO CENTER, 90 SOUTH 7TH STREET, MINNEAPOLIS, MN, 55402-3901, US	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	41 Drawing Page(s)	
LINE COUNT:	3430	

AB Methods and systems are described for diagnosis and/or treatment of physical or mental conditions, disorders, disabilities or illnesses, injuries, and chronic conditions. According to one embodiment, a communications network that provides a closed communication service to facilitate and encourage affective communication, activity stimulating communication and/or intellectually stimulating communication among members of a caregroup and a target of the caregroup is used as a method of treatment for (i) a physical or mental condition, disorder, disability or illness, (ii) an injury, and/or (iii) a chronic condition of the target. According to another embodiment, such a closed communication service is used as a method of facilitating (i) diagnosis of the target's mental or physical status, (ii) evaluation of the target's response to service stimuli and treatments and condition over time; and/or (iii) making prognoses regarding progression of physical or mental condition, disability, disease or chronic conditions of the target.

L12 ANSWER 3 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2005:111532 USPATFULL

TITLE: Identification of biomarkers for detecting pancreatic cancer

INVENTOR(S): Chan, Daniel W., Clarksville, MD, UNITED STATES  
Zhang, Zhen, Dayton, MD, UNITED STATES  
Koopmann, Jens, Bochum, GERMANY, FEDERAL REPUBLIC OF  
Goggins, Michael, Baltimore, MD, UNITED STATES

10/762998

White, C. Nicole, Baltimore, MD, UNITED STATES  
Fung, Eric, Mountain View, CA, UNITED STATES  
Meng, Xiao-Ying, Fremont, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005095611	A1	20050505
APPLICATION INFO.:	US 2004-836649	A1	20040430 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-467501P	20030502 (60)
	US 2004-542618P	20040205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Peter F. Corless, EDWARDS & ANGELL, LLP, P.O. Box 55874, Boston, MA, 02205, US	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	3207	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of qualifying pancreatic cancer status in a subject comprising: (a) measuring at least one of the disclosed biomarkers in a sample from the subject and (b) correlating the measurement with pancreatic cancer status. The invention further relates to kits for qualifying pancreatic cancer status in a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2004:196456 USPATFULL  
TITLE: Systems and methods for facilitated feed supplementation  
INVENTOR(S): Minard, Rebecca M., Sherborn, MA, UNITED STATES  
Gisholt, Paal C., Sherborn, MA, UNITED STATES  
PATENT ASSIGNEE(S): Precision Equine Supplement, Sherborn, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004151760	A1	20040805
APPLICATION INFO.:	US 2004-762998	A1	20040122 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-679752, filed on 5 Oct 2000, GRANTED, Pat. No. US 6733771		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205		
NUMBER OF CLAIMS:	39		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Page(s)		
LINE COUNT:	725		

AB The present invention provides a multi-compartment package, a machine for the automated or semi-automated packaging of a diverse array of animal supplements into such packaging, and a process allowing efficient procurement and fulfillment of custom supplement orders.

Searcher : Shears 571-272-2528



## L12 ANSWER 5 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2004:116647 USPATFULL  
 TITLE: Systems and methods for facilitated feed  
 supplementation  
 INVENTOR(S): Minard, Rebecca M., Sherborn, MA, United States  
 Gisholt, Paal C., Sherborn, MA, United States  
 PATENT ASSIGNEE(S): SmartPak Equine, L.L.C., Pembroke, MA, United  
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6733771	B1	20040511
APPLICATION INFO.:	US 2000-679752		20001005 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-158207P	19991007 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Levy, Neil S.	
LEGAL REPRESENTATIVE:	Coreless, Peter F., Edwards & Angell, LLP	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 11 Drawing Page(s)	
LINE COUNT:	744	

AB The present invention provides a multi-compartment package, a machine for the automated or semi-automated packaging of a diverse array of animal supplements into such packaging, and a process allowing efficient procurement and fulfillment of custom supplement orders.

## L12 ANSWER 6 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2004:24440 USPATFULL  
 TITLE: Packaging containing fragrance  
 INVENTOR(S): Popplewell, Lewis Michael, Morganville, NJ, UNITED  
 STATES  
 Henson, Lulu S., Plainsboro, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004018278	A1	20040129
APPLICATION INFO.:	US 2003-441574	A1	20030520 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-202958, filed on 25 Jul 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Joseph F. Leightner, Esq., INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 West 57th Street, New York, NY, 10019		
NUMBER OF CLAIMS:	40		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	836		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Packaging materials and packages that transfer fragrances to foods and other products via the vapor phase are disclosed. The present

10/762998

invention provides a source of desired fragrance, a suitable environment for vapor transfer, and an appropriate food substrate to which flavor and fragrance is added. Examples of the source of fragrance can be a packaging film containing fragrance, a sachet of absorbed flavor material, a tape or label applied to the inside of a package, and a flavor diffusing granule or an active system for delivering flavor vapor to the environment. Materials that are preferably treated using the present invention include snacks, confections, baked goods, fresh plant materials, cereals and beverages, as well as non-food products. The time required for flavor transfer is dependent primarily on the volatility and concentration of the fragrances, absorptive capacity of the food, and the intensity of the flavor desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:237907 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis of colon cancer

INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrist, Heather, Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES,  
98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166064	A1	20030904
APPLICATION INFO.:	US 2002-99926	A1	20020314 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8531	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

Searcher : Shears 571-272-2528

10/762998

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:106233 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis of pancreatic cancer

INVENTOR(S): Benson, Darin R., Seattle, WA, UNITED STATES  
Kalos, Michael D., Seattle, WA, UNITED STATES  
Lodes, Michael J., Seattle, WA, UNITED STATES  
Persing, David H., Redmond, WA, UNITED STATES  
Hepler, William T., Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES,  
98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073144	A1	20030417
APPLICATION INFO.:	US 2002-60036	A1	20020130 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333626P	20011127 (60)
	US 2001-305484P	20010712 (60)
	US 2001-265305P	20010130 (60)
	US 2001-267568P	20010209 (60)
	US 2001-313999P	20010820 (60)
	US 2001-291631P	20010516 (60)
	US 2001-287112P	20010428 (60)
	US 2001-278651P	20010321 (60)
	US 2001-265682P	20010131 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701  
FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 17

EXEMPLARY CLAIM: 1

LINE COUNT: 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2002:272801 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis of colon cancer

INVENTOR(S): Stolk, John A., Bothell, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Chenault, Ruth A., Seattle, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

Searcher : Shears 571-272-2528

10/762998

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES,  
98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002150922	A1	20021017
APPLICATION INFO.:	US 2001-998598	A1	20011116 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-304037P	20010710 (60)
	US 2001-279670P	20010328 (60)
	US 2001-267011P	20010206 (60)
	US 2000-252222P	20001120 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701  
FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 17

EXEMPLARY CLAIM: 1

LINE COUNT: 9233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2002:243051 USPATFULL

TITLE: Compositions and methods for the therapy and  
diagnosis of ovarian cancer

INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES  
Jones, Robert, Seattle, WA, UNITED STATES  
Harlocker, Susan L., Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES,  
98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25718	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Searcher : Shears 571-272-2528

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 11 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2002:214624 USPATFULL  
 TITLE: Anastomosis system and methods for use  
 INVENTOR(S): Stevens, Walter J., Woodbury, MN, UNITED STATES  
 Chen, Eunice, Menlo Park, CA, UNITED STATES  
 Smith, Jessica, Granite Bay, CA, UNITED STATES  
 Oguss, Douglas, Northbrook, IL, UNITED STATES  
 O'Connell, Mary K., Palo Alto, CA, UNITED STATES  
 Story, Jay, Boise, ID, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002116018	A1	20020822
APPLICATION INFO.:	US 2001-10960	A1	20011109 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US14689, filed on 26 May 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-136707P	19990528 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Bret E. Field, Bozicevic, Field and Francis LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA, 94025	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	1083	

AB An anastomosis system and methods for its use in end-to-side anastomoses are provided. The subject anastomosis system includes nesting, first and second structural means which are each tubular in structure and have a lip at at least one end. In performing an end-to-side anastomosis according to the subject invention, the subject anastomosis system is used to stably attach the graft vessel to the side of the host vessel in a manner that provides for fluid communication between the lumens of the graft and host vessels. Also provided are kits that include the subject systems. The subject anastomosis systems and methods find use in a variety of different anastomosis applications, including vascular anastomoses, and particular proximal anastomoses.

L12 ANSWER 12 OF 14 USPATFULL on STN

ACCESSION NUMBER: 90:48977 USPATFULL  
 TITLE: Microwave cooking carton for browning and crisping food products

10/762998

INVENTOR(S): Oppenheimer, Douglas F., 2912 Gekeler La., Boise,  
ID, United States 83702

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4935592		19900619
APPLICATION INFO.:	US 1988-279746		19881205 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Leung, Philip H.		
LEGAL REPRESENTATIVE:	Larson and Taylor		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	229		

AB A microwavable package for browning the surface of a plurality of small food articles is disclosed. The package is disposable and includes an outer carton in which a microwave susceptor is housed. The susceptor is a unitary device which includes a plurality of compartments therein. Each compartment is sized to house a single food product and maintain physical contact between the susceptor means and a substantial portion of the food product. Upon heating in a microwave oven the physically-contacted portion of the surface of food product is browned or crisped to produce an aesthetically pleasing food.

L12 ANSWER 13 OF 14 USPATFULL on STN

ACCESSION NUMBER: 84:39505 USPATFULL  
TITLE: Plural container package  
INVENTOR(S): Miller, John L., Toledo, OH, United States  
PATENT ASSIGNEE(S): Owens-Illinois, Inc., Toledo, OH, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4460084		19840717
APPLICATION INFO.:	US 1982-417016		19820913 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dixson, Jr., William T.		
ASSISTANT EXAMINER:	Ehrhardt, Brenda J.		
LEGAL REPRESENTATIVE:	Farquer, Thomas L., Click, M. E.		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	564		

AB A plural container packaged for securing together a plurality of identical containers, each said container having an open neck finish, an outstanding bead portion disposed below said finish portion, an angled shoulder portion disposed below said bead portion and an elongate hollow enlarged diameter main body portion having a closed bottom, in communication with said finish opening. The package includes a plurality of such containers, in a regular geometric array, with a unitary cover shroud overlaying each container in the array such that the upper portion of the cover shroud is subjacent to the bead portion of the containers and the lower portion of the cover shroud extends approximately to the midpoint of the container main body portion. A first container

Searcher : Shears 571-272-2528

10/762998

securing means interconnects each container at a point immediately subjacent to the bead portion of the container and superjacent to the cover shroud. A second container securing means is disposed about the container array and overlays the lowermost portion of the cover shroud.

L12 ANSWER 14 OF 14 USPATFULL on STN

ACCESSION NUMBER: 76:7589 USPATFULL

TITLE: Anthelmintic composition and method of use

INVENTOR(S): Alford, Booker Taliaferro, Trenton, NJ, United States

PATENT ASSIGNEE(S): American Cyanamid Company, Stamford, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3937825		19760210
APPLICATION INFO.:	US 1974-514726		19741015 (5)
RELATED APPLN. INFO.:	Continuation in-part of Ser. No. US 1973-399651, filed on 21 Sep 1973, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Turner, V. D.		
LEGAL REPRESENTATIVE:	Polyn, Denis A.		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
LINE COUNT:	233		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An anthelmintic composition comprising a combination of 0,0-dimethyl (2,2,2-trichloro-1-hydroxyethyl)phosphonate and 1-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole hydrochloride and a method for control of gastrointestinal, cutaneous and lung-infesting parasites in equine species.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

(FILE 'HCAPLUS' ENTERED AT 17:35:00 ON 31 JAN 2006)

L1 2 SEA FILE=REGISTRY ABB=ON PLU=ON (CALCIUM OR VITAMINS)/CN

L2 10 SEA FILE=REGISTRY ABB=ON PLU=ON (PHOSPHATE/CN OR "PHOSPHATE (32PO4)"/CN OR "PHOSPHATE (H2PO4-)/CN OR "PHOSPHATE (H2PO41-)/CN OR "PHOSPHATE (HPO42-)/CN OR "PHOSPHATE (P2O74-)/CN OR "PHOSPHATE (P4O123-)/CN OR ("PHOSPHATE (P5O143-)/CN OR "PHOSPHATE (P6O186-)/CN) OR ("PHOSPHATE (PO3-)/CN OR "PHOSPHATE (PO31-)/CN OR "PHOSPHATE (PO32-)/CN) OR "PHOSPHATE (PO43-)/CN OR "PHOSPHATE (PO4H2-)/CN

L3 12 SEA FILE=REGISTRY ABB=ON PLU=ON L1 OR L2

L4 50681 SEA FILE=HCAPLUS ABB=ON PLU=ON (MULTI OR MULTIPLE OR PLURAL?) (S) (SECTION? OR COMPARTMENT? OR COMPONENT? OR CONTAINER? OR SUBCOMPARTMENT? OR SUBCONTAINER?)

L5 636 SEA FILE=HCAPLUS ABB=ON PLU=ON L4 (S) (PACKAG? OR PACKET OR PACK)

L13 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L5 (S) (UNIFIED OR UNIFY? OR UNITAR?)

L14 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L3 OR FEED? OR FOOD? OR SUPPLEMENT? OR NUTRITION? OR NUTRIENT OR VITAMIN OR VIT OR MINERAL OR CHEMICAL OR ELECTROLYT? OR PROTEIN OR

Searcher : Shears 571-272-2528